Thursday, November 13, 2014

Top Safest Companies To Buy Right Now

What kind of investor are you? If you don't know, you might have a problem. It's useful to have a handle on your investment strategy, so that you can better focus on it.

There are many different ways to categorize investing. For example, a Goldilocks-like approach might divide investing strategies into these groups:

Too-aggressive investing: This approach puts your dollars in danger. It can include any of a host of riskier-than-average types of investments, such as options, commodities, currency bets, penny stocks, and even lottery tickets. It's true that some options strategies can be conservative, but many are not, and it's very, very common for options to expire unexercised and worthless.

Too-cautious investing: It might seem smart to be very conservative with your money, but if you do that, it might not grow enough to support you in retirement. That's especially true these days, in our environment of ultra-low interest rates. With inflation historically averaging about 3% annually in the U.S., even earning 2% in your bank account or via a bond or CD will leave you losing purchasing power over time.

Just-right investing: For many people, a long-term portfolio mixed with both stocks and bonds is a sound way to grow your net worth.

The bond world features many kinds of bonds, such as government bonds, municipal bonds, and corporate bonds. Government bonds, such as U.S. Treasury bills, bonds, and notes, are the safest, backed by the U.S. government. They pay interest that's taxable on your federal tax return, but is exempt from state and local taxes. Municipal bonds can be riskier, as some local governments are on somewhat shaky ground, but they can therefore offer higher interest rates and their interest is exempt not only from state and local taxes, but also from federal taxes. Corporate bonds are issued by companies that want to raise money. They, too, offer rates higher than government bonds, and their interest is not tax-exempt. In general, the higher their interest rate, the lower their credit rating and healthiness.

Stock investing approaches
A sound stock investment strategy is hard to beat, for long-term growth. Here's a quick rundown of some key approaches. Note that many investors engage in one or more of them -- they're not all mutually exclusive.

Best Retail Stocks To Own Right Now: eLong Inc.(LONG)

eLong, Inc. operates as an online travel service provider in the People?s Republic of China. The company provides its customers with travel information and the ability to book rooms, air tickets, vacation packages, and other travel related services utilizing call center and Web-based distribution technologies. It facilitates the customers to book rooms in approximately 10,000 hotels in 450 cities across China, and fulfills air ticket reservations in approximately 80 cities across China. In addition, the company offers the ability to book rooms at approximately 100,000 hotels outside of China; and provides the customers informative content relevant to hotel and air travel decisions, including tourist and event site destination information, hotel facility information, and photos. eLong markets its services through online marketing, traditional media advertising, co-marketing with established brands of other companies, and direct marketing. The company was founded in 1999 and is headquartered in Beijing, the People?s Republic of China. eLong, Inc. operates as a subsidiary of Expedia Asia Pacific Limited.

Advisors' Opinion:
  • [By Seth Jayson]

    eLong (Nasdaq: LONG  ) reported earnings on May 13. Here are the numbers you need to know.

    The 10-second takeaway
    For the quarter ended March 31 (Q1), eLong beat expectations on revenues and beat expectations on earnings per share.

Top Safest Companies To Buy Right Now: H&Q Life Sciences Investors (HQL)

H&Q Life Sciences Investors (the Fund) is a diversified, closed-end management investment company. The Fund's investment objective is long-term capital appreciation through investment in life science companies (including biotechnology, pharmaceutical, diagnostics, managed healthcare and medical equipment, hospitals, healthcare information technology and services, devices and supplies) agriculture and environmental management. The Fund invests primarily in securities of public and private companies.

The Fund may invest in venture capital and other restricted securities if these securities would comprise 40% or less of net assets. The Fund may purchase and sell (or write) put or call options on any security in which it is permitted to invest. It may purchase and sell (write) options on stock indices (index options). H&Q Life Sciences Investors��investment advisor is Hambrecht & Quist Capital Management, LLC.

Advisors' Opinion:
  • [By Nate Pile]

    This recommended fund��ambrecht & Quist Life Sciences Fund (HQL)��as also our top pick last year, and the fund rose 44% in 2013.

    In addition to rising in value, the fund has a dividend policy of paying out 2% of its net asset value of each quarter.

  • [By Harry Domash, Publisher, DividendDetective and Winning Investing]

    Harry Domash: Yeah, in fact, H&Q Life Sciences, ticker (HQL), is actually a closed-end fund, but it invests entirely in biotech and pharmaceutical companies, and if you look around the world, the investing stocks right now—besides the social media stocks—that's really the one area that has had a lot of recent growth and we expect that to continue.

    I think the closed-end fund, and we'll get into that maybe a little bit later, but closed-end funds are a good way to cover it, when you're talking about a sector like that.

    Johnson & Johnson is an interesting case, because, as you know, Johnson & Johnson is a big company that invests, and that owns a lot of different companies itself in the medical field.

    You know, it owns hundreds of operating companies and it's primarily in the pharmaceuticals, and medical devices, and in consumer products, but Johnson & Johnson was a mismanaged company for a while and they were really underperforming their peers.

    In fact, some of their factories were closed, their pharmaceutical production factories were forcibly closed by the government because they didn't meet standards, but they were taken over by a new CEO a few years ago, two or three years ago, and now things are improving, so Johnson & Johnson is kind of coming from down and out to being a leading company again.

    They've got a lot of products, cancer-type products, and things on the pipeline and it just seems like things are going very well so we have hopes that Johnson & Johnson has reported the last two quarters are the first ones that have really been decent, they really showed growth, and then we expect that to accelerate so we're pretty hot on Johnson & Johnson now.

    Steve Halpern: One particularly interesting portfolio that you maintain that I haven't seen anywhere else is based on closed-end funds that pay monthly dividends&mdash

Top Safest Companies To Buy Right Now: NetScout Systems Inc.(NTCT)

NetScout Systems, Inc. engages in the design, development, manufacture, marketing, sale, and support of unified service delivery management, service assurance, and application and network performance management solutions worldwide. It offers nGenius Service Assurance Solution, an integrated unified service delivery management platform that provides application and service performance intelligence to enable organizations to assure network and application performance and user experience. This solution?s capabilities include intelligent early warning and service visualization, packet-level forensic analysis, planning and optimization, and service and policy validation, as well as network, application, and service performance management. The company also provides Sniffer Analysis software suite that offers a direct connection to nGenius InfiniStream appliances for forensic analysis and packet data mining to exploit the information contained within network packets; and a view i nto IP network packets revealing granular information about network and application interactions, response time, and latency metrics. In addition, NetScout Systems, Inc. offers Sniffer Portable Analyzer product family that provides portable network and application analysis capabilities for field deployments. The company?s solutions support a range of enterprise information technology operations and are deployed by telecommunication service providers. It markets and distributes its products through direct sales force, as well as through strategic channel partners, including distributors, value added resellers, and systems integrators to financial, healthcare, manufacturing, retail, technology, utilities, education, and the public sectors. The company was founded in 1984 and is headquartered in Westford, Massachusetts.

Advisors' Opinion:
  • [By Seth Jayson]

    There's no foolproof way to know the future for NetScout Systems (Nasdaq: NTCT  ) or any other company. However, certain clues may help you see potential stumbles before they happen -- and before your stock craters as a result.

  • [By josieclarks]

    Posted-In: Markets

      Around the Web, We're Loving... Learn to Use Trading Platforms Like Hedge Fund Traders do Rumsfeld: Denial of Benefits to Fallen Soldiers' Families 'Inexcusable' Come See How the Pro's Trade in this Exclusive Webinar Facebook, Baidu Lead Big Caps Beating Shutdown What Should You Know About AMZN? Most Popular UPDATE: So

Top Safest Companies To Buy Right Now: TICC Capital Corp.(TICC)

TICC Capital Corp., a business development company, operates as a closed-end, non-diversified management investment company. The firm invests in both public and private companies. It invests in secured and unsecured senior debt, subordinated debt, junior subordinated debt, preferred stock, and common stock. The firm primarily invests in debt and/or equity securities of technology-related companies that operate in the computer software, Internet, information technology infrastructure and services, media, telecommunications and telecommunications equipment, semiconductors, hardware, technology-enabled services, semiconductor capital equipment, medical device technology, diversified technology, and networking systems sectors. It concentrates its investments in companies having annual revenues of less than $200 million and a market capitalization or enterprise value of less than $300 million. The firm invests between $5 million and $30 million per transaction. It seeks to exit its investments within 7 years. It serves as the investment adviser to TICC. The company was formerly known as Technology Investment Capital Corp. and changed its name to TICC Capital Corp. in December 2007. TICC Capital Corp. was founded in 2003 and is headquartered in Greenwich, Connecticut.

Advisors' Opinion:
  • [By Brian Pacampara]

    Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, closed-end asset manager TICC Capital Corp. (NASDAQ: TICC  ) has earned a respected four-star ranking.

  • [By Monica Gerson]

    TICC Capital (NASDAQ: TICC) is estimated to report its Q4 earnings at $0.28 per share on revenue of $28.43 million.

    Fuel-Tech (NASDAQ: FTEK) is expected to post its Q4 earnings at $0.06 per share on revenue of $29.00 million.

Top Safest Companies To Buy Right Now: Nash-Finch Company(NAFC)

Nash-Finch Company operates as a wholesale food distributor in the United States. The company?s Military segment distributes grocery products to the United States military commissaries and exchanges in the United States and the District of Columbia, Europe, Puerto Rico, Cuba, the Azores, Egypt, and Bahrain. Its Food Distribution segment sells and distributes various branded and private label grocery products and perishable food products to approximately 1,500 independent retail locations through its 14 distribution centers. This segment also provides various services, including promotional, advertising, and merchandising programs; installation of computerized ordering, receiving, and scanning systems; retail equipment procurement assistance; accounting, budgeting, and payroll contract services; consumer and market research; remodeling and store development services; supply chain through Internet services; and securing existing grocery stores. The company?s Retail segment operates corporate-owned grocery stores under the Sun Mart, Econofoods, AVANZA, Family Thrift Center, Pick ?n Save, Family Fresh Market, Prairie Market, Saver?s Choice, Wally?s Supermarkets, and Wholesale Food Outlet banners primarily in the states of Colorado, Iowa, Minnesota, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin. This segment?s conventional grocery stores offer a range of grocery products and services, such as fresh meat counters, delicatessens, bakeries, eat-in cafes, pharmacies, banks, and floral departments, as well as provide check cashing, fax services, and money transfer services. As of December 31, 2011, the company served 93 retail stores operating under the IGA banner and 50 retail stores under the Food Pride banner; and operated 43 conventional supermarkets, 1 AVANZA grocery store, 1 Wholesale Food Outlet grocery store, and 1 Saver?s Choice store. Nash-Finch Company was founded in 1885 and is based in Minneapolis, Minnesota.

Advisors' Opinion:
  • [By Alex Planes]

    Sysco has avoided the margin compression suffered by chicken producers Tyson (NYSE: TSN  ) and Cal-Maine Foods (NASDAQ: CALM  ) and which was more deeply felt by smaller food-service operator Nash-Finch (NASDAQ: NAFC  ) . (It is omitted from this chart due to its drop into outright negative operating margin territory (a decline of roughly 250% in two years.) However, fellow food-service company United Natural Foods (NASDAQ: UNFI  ) has actually improved its margins, and restaurant chains both large and small (well, mid-size) have done an admirable job of holding the margin line in the face of rising input costs. So it appears that scale alone isn't enough to help Sysco outrun the rising costs of its products.

Top Safest Companies To Buy Right Now: Novo Nordisk A/S (NVO)

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products in Denmark and internationally. The company operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes care segment covers insulins, oral antidiabetic drugs, and other protein-related products and projects comprising glucagon and protein-related delivery systems, as well as GLP-1 analogue. The Biopharmaceuticals segment provides products in the areas of haemophilia, growth hormone therapy, hormone replacement therapy, and inflammation therapy. Its products are marketed and distributed through subsidiaries, distributors, and independent agents in 180 countries. Novo Nordisk A/S has a collaboration agreement with Archimedes, Inc. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

Advisors' Opinion:
  • [By Rich Duprey]

    What started with the Food Network not renewing her TV show contract has now turned into a complete rout, with major corporations including Wal-Mart (NYSE: WMT  ) , Target, Home Depot, and Novo Nordisk (NYSE: NVO  ) all dropping their association with her.

  • [By Dan Carroll]

    While Big Pharma's facing increased scrutiny from regulators, investors looking for one of the best pharmaceutical stocks in this growing market could do worse than looking into Novo Nordisk (NYSE: NVO  ) . The Danish pharmaceutical power has carved out a lucrative niche in China's growing diabetes market, becoming the market leader in this industry with a 37% market share. If Novo can avoid any Chinese crises of its own in the difficult-to-maneuver market, its sharp Chinese sales growth -- 28% last year -- could continue and fuel this stock's future.

  • [By Max Macaluso, Ph.D.]

    Last week, pharmaceutical giant Eli Lilly (NYSE: LLY  ) announced that its cancer drug candidate enzastaurin failed its late-stage clinical trial. Despite this news, shares remained practically flat following the announcement. Was this drug central to Lilly's pipeline, or was it one of many oncology drugs that the company is testing? Should investors instead be worried about Lilly's upcoming patent expirations? What about the ever-present competition from diabetes powerhouse��Novo Nordisk (NYSE: NVO  ) ? Health-care analyst Max Macaluso discusses these topics in the following video.

Top Safest Companies To Buy Right Now: China Biologic Products Inc.(CBPO)

China Biologic Products, Inc., a biopharmaceutical company, through its subsidiaries, engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People?s Republic of China. It offers Human Albumin for the treatment of shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also offers Human Hepatitis B Immunoglobulin for the prevention of measles and contagious hepatitis; Human Immunoglobulin and Human Immunoglobulin for Intravenous Injection products for original immunoglobulin deficiency, secondary immunoglobulin deficiency, and auto-immune deficiency diseases; and Thymopolypeptides Injection that is used in the treatment of various original and sec ondary T-cell deficiency syndromes, auto-immune deficiency diseases, and a range of cell immunity deficiency diseases, as well as assists in the treatment for tumors. In addition, it provides Human Rabies Immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; Human Tetanus Immunoglobulin for the prevention and therapy of tetanus; and Placenta Polypeptide that is used for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia caused by various reasons, as well as assists in postoperative heating. The company?s products under development comprise Human Prothrombin Complex Concentrate; Human Coagulation Factor VIII; Human Hepatitis B Immunoglobulin (PH4) for Intravenous Injection; Human Fibrinogen; Varicella Hyperimmune Globulins; and Human Immunoglobulin for Intravenous Injection. The company is based in Beijing, the People's Republic of China.

Advisors' Opinion:
  • [By Jake L'Ecuyer]

    Leading and Lagging Sectors
    Healthcare sector moved up 0.39 percent, with Keryx Biopharmaceuticals (NASDAQ: KERX) moving up 15 percent to gain the top spot. Top gainers in the sector included China Biologic Products (NASDAQ: CBPO), with shares up 7.4 percent, and Laboratory Corp. of America Holdings (NYSE: LH), with shares up 5.5 percent.

  • [By Jake L'Ecuyer]

    Leading and Lagging Sectors
    Healthcare sector moved up 0.39 percent, with Keryx Biopharmaceuticals (NASDAQ: KERX) moving up 15 percent to gain the top spot. Top gainers in the sector included China Biologic Products (NASDAQ: CBPO), with shares up 7.4 percent, and Laboratory Corp. of America Holdings (NYSE: LH), with shares up 5.5 percent.

No comments:

Post a Comment